Safety and Efficacy Study of HET Bipolar System for Treatment of Stage I and Stage II Hemorrhoids
Primary Purpose
Hemorrhoids, Internal
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
HET Bipolar System
Sponsored by
About this trial
This is an interventional treatment trial for Hemorrhoids, Internal
Eligibility Criteria
Inclusion Criteria:
- Subject over 21 years of age
- General good health
- Subject undergoing elective treatment for Stage I or Stage II internal hemorrhoids
- Chronic bleeding from Stage I or Stage II internal hemorrhoids (at least weekly occurrence
- Failure of prior medical management
Exclusion Criteria:
- Under 21 years of age.
- Gastrointestinal bleeding from source other than their internal hemorrhoids
- Active proctitis
- Inflammatory bowel disease
- HIV positive or immunocompromised
- Rectal wall prolapse
- Stage III and Stage IV hemorrhoids
- Medical conditions requiring anticoagulants and/or subject to receive anticoagulants within 7 days of initial examination
- Pregnancy
- Rectal malignancy
- Hepatitis C
- Liver cirrhosis
- End stage renal disease
- Receiving chemotherapy
- Advanced malignancy
- Documented bleeding diathesis
- Treatment with an investigational drug or medical device in the past 30 days
Sites / Locations
- University Hospitals Case Medical Center
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
HET Arm
Arm Description
Active arm. A single procedure with HET was used to treat Grade I and Grade II hemorrhoids
Outcomes
Primary Outcome Measures
Number of Participants With Resolution of Symptoms
The primary endpoint analysis was the resolution of symptoms, including resolution of bleeding and prolapse, if present prior to treatment
Secondary Outcome Measures
Incidence of Recurrence of Pre-procedure Symptoms
Recurrence of pre-procedure symptoms after initial improvement
Recurrence of Symptoms That Had Resolved With Treatment
Number of patients with recurrence of symptoms defined as external thrombosed hemorrhoids, infection, mucous discharge, new fissure, stenosis and delayed healing.
Pain Recorded Yes or No on Visual Analog Scale (VAS)
Patient reported pain on 10 point scale where 0 =No Pain and > 0 = Pain with 10 being the worst.
Mean Pain Score Based on the Visual Analog Pain Scale
Mean pain score based on the Visual Analog pain scale. Patient reported pain on 10 point scale where 0 =No Pain and > 0 = Pain with 10 being the worst.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01841970
Brief Title
Safety and Efficacy Study of HET Bipolar System for Treatment of Stage I and Stage II Hemorrhoids
Official Title
Multi-Center, Prospective Study of the Safety and Efficacy of the HET Bipolar System for Treatment of Stage I and Stage II Hemorrhoids
Study Type
Interventional
2. Study Status
Record Verification Date
November 2016
Overall Recruitment Status
Completed
Study Start Date
April 2013 (undefined)
Primary Completion Date
November 2014 (Actual)
Study Completion Date
January 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medtronic - MITG
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Hemorrhoids are vascular cushions in the anal canal. People are normally born with hemorrhoids, and the presence of hemorrhoids does not imply disease. However, hemorrhoids typically cause symptoms when they enlarge over time. There are two types of hemorrhoids- External Hemorrhoids and Internal Hemorrhoids.
Current minimally invasive technologies for the treatment of internal hemorrhoids are associated with several drawbacks that include high rate of recurrence and a need for repetitive procedures, frequent post-procedural pain or significant discomfort, intra-operative pain and technically demanding. The purpose of this study is to determine whether the HET Bipolar System is safe and effective in the treatment of Stage I and Stage II hemorrhoids (internal hemorrhoids). The HET Bipolar System is a new alternative device for the minimally invasive treatment of Stage I and Stage II hemorrhoids that incorporate design features with the intent of resolving each of the major limitations of currently available technology.
Detailed Description
In this study, the investigators will use the HET Bipolar System for the treatment of Stage I and Stage II hemorrhoids, where significant tissue prolapse is not present. The hemorrhoids are treated by bipolar ligation of the superior hemorrhoidal blood supply.
Each prospective subject will be screened for inclusion and exclusion criteria at least one week prior to treatment. All patients undergoing treatment will review and sign the study Informed Consent prior to their procedure.
One to three internal hemorrhoids will be treated in one therapeutic session. The number will be based on the investigator's judgment of which quadrants are symptomatic. Evaluations will be recorded for all treated subjects immediately following treatment. Subjects will be followed at 1, 3, and 6 months post procedure unless complications are reported between scheduled follow-up dates. At each post treatment follow-up, a report will be made of pain/discomfort, bleeding, medication use, itching, presence of adverse events or complications and need for supplemental treatment. Face-to-face follow-up evaluations will include anoscopic evaluation and assessment of hemorrhoid and other relevant symptoms.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hemorrhoids, Internal
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Actual)
8. Arms, Groups, and Interventions
Arm Title
HET Arm
Arm Type
Other
Arm Description
Active arm. A single procedure with HET was used to treat Grade I and Grade II hemorrhoids
Intervention Type
Device
Intervention Name(s)
HET Bipolar System
Intervention Description
The HET Bipolar System is used to treat hemorrhoids by bipolar ligation of the superior hemorrhoidal blood supply.
Primary Outcome Measure Information:
Title
Number of Participants With Resolution of Symptoms
Description
The primary endpoint analysis was the resolution of symptoms, including resolution of bleeding and prolapse, if present prior to treatment
Time Frame
Post treatment at Month1, Month 3, Month 6
Secondary Outcome Measure Information:
Title
Incidence of Recurrence of Pre-procedure Symptoms
Description
Recurrence of pre-procedure symptoms after initial improvement
Time Frame
Post treatment at Month 1, Month 3, and Month 6
Title
Recurrence of Symptoms That Had Resolved With Treatment
Description
Number of patients with recurrence of symptoms defined as external thrombosed hemorrhoids, infection, mucous discharge, new fissure, stenosis and delayed healing.
Time Frame
Post treatment at Month 1, Month 3, Month 6
Title
Pain Recorded Yes or No on Visual Analog Scale (VAS)
Description
Patient reported pain on 10 point scale where 0 =No Pain and > 0 = Pain with 10 being the worst.
Time Frame
Post treatment at Month 1, Month 3, Month 6
Title
Mean Pain Score Based on the Visual Analog Pain Scale
Description
Mean pain score based on the Visual Analog pain scale. Patient reported pain on 10 point scale where 0 =No Pain and > 0 = Pain with 10 being the worst.
Time Frame
Post treatment at Month 1, Month 3, Month 6
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subject over 21 years of age
General good health
Subject undergoing elective treatment for Stage I or Stage II internal hemorrhoids
Chronic bleeding from Stage I or Stage II internal hemorrhoids (at least weekly occurrence
Failure of prior medical management
Exclusion Criteria:
Under 21 years of age.
Gastrointestinal bleeding from source other than their internal hemorrhoids
Active proctitis
Inflammatory bowel disease
HIV positive or immunocompromised
Rectal wall prolapse
Stage III and Stage IV hemorrhoids
Medical conditions requiring anticoagulants and/or subject to receive anticoagulants within 7 days of initial examination
Pregnancy
Rectal malignancy
Hepatitis C
Liver cirrhosis
End stage renal disease
Receiving chemotherapy
Advanced malignancy
Documented bleeding diathesis
Treatment with an investigational drug or medical device in the past 30 days
Facility Information:
Facility Name
University Hospitals Case Medical Center
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Safety and Efficacy Study of HET Bipolar System for Treatment of Stage I and Stage II Hemorrhoids
We'll reach out to this number within 24 hrs